Wednesday Lunch feat. Bill Cassidy

Session Overview and Mission Context

• The session "Walking the Drug Pricing Tightrope" is hosted by Esther Krofa, Senior Director of Faster Cures, at the Milken Institute's Future of Health Summit.
• Faster Cures aims to accelerate medical research by addressing barriers such as lack of collaboration, misaligned incentives, and capital allocation issues.
• Current statistics cited indicate nearly 10,000 diseases exist globally, yet treatments are available for only 500 of them.
• The organization emphasizes that delays in drug approval and access directly cost lives, citing HIV/AIDS as a model where patient advocacy successfully transformed a death sentence into a manageable chronic condition.
• Krofa states the goal is to balance scientific innovation with affordability, asserting that both goals are achievable simultaneously.

Senator Bill Cassidy: Senate Dynamics and Legislative Support

• Senator Bill Cassidy (R-LA) notes that while nine Republicans on the Senate Finance Committee opposed a specific conference package, a broader coalition of the majority of Senate Republicans is expected to support the final legislation.
• Cassidy argues the current package strikes a necessary balance between lowering drug costs and maintaining the financial incentives required for innovation.
• Regarding Senate Majority Leader Mitch McConnell's public silence, Cassidy suggests the leader is "keeping his powder dry" pending House action rather than actively blocking the bill.
• Cassidy acknowledges that inaction on drug pricing could be politically detrimental for Republicans in the upcoming election year.
• He highlights two recent legislative successes: a bill closing a Medicaid rebate loophole expected to save taxpayers $3.1 billion, and legislation eliminating "gag clauses" that prevented pharmacists from informing patients of lower cash prices.

Pharmaceutical Profitability and Industry Responsibility

• Cassidy dismisses the premise that pharma companies' reported $47 billion in collective earnings (from sponsors like Pfizer, Amgen, and Genentech) is inherently excessive, framing the debate around whether taxpayers can afford the products rather than the absolute profit margin.
• He distinguishes between responsible innovation (e.g., continued investment in Alzheimer's cures despite high failure rates) and irresponsible arbitrage (e.g., selling off-patent drugs in the U.S. at $48,000 when available for $8,000 in Canada).
• Cassidy rejects the "black-and-white" characterization of the industry, stating that while no company is "pure as the driven snow," there are no entities that are purely evil.
• He cites a Kaiser Family Foundation poll (conducted in 2005) showing 70% of respondents believe drug companies prioritize profits over people and 65% support more government regulation.

Innovative Pricing Models: The "Netflix" Subscription Approach

• Cassidy explains the "Netflix" or subscription pricing model, where a fixed fee covers treatment for an indefinite period or specific patient population, regardless of the number of prescriptions filled.
• He notes that Louisiana employs a variation of this model to lower costs for incarcerated populations and Medicaid recipients, who operate on fixed budgets.
• The model was detailed in a JAMA publication co-authored by Cassidy, Peter Bach, and Mark Trusham, and in a Stat News article by Cassidy specifically regarding gene therapy financing.
• Cassidy uses sickle cell anemia as a case study, noting that $1.5 million gene therapies administered in the first week of life could save $50 million in lifetime healthcare costs, whereas treatment at age 45 yields no savings due to cumulative organ damage.
• He suggests the subscription model is a necessary mechanism for scaling expensive gene therapies to populations like the 700,000+ Americans with sickle cell anemia.

Government Negotiation and Innovation Risks

• Senator Cassidy reiterates his opposition to direct government price negotiation, quoting, "Absolute power corrupts absolutely," arguing it would give the government unchecked pricing power.
• He warns that if the federal government mandates prices with a penalty of forfeiting 65% to 95% of gross receipts for non-compliance, venture capital will withdraw from high-risk areas like Alzheimer's research.
• Cassidy distinguishes the current House proposals from the Veterans Affairs (VA) system, arguing the VA represents a small portion of the market and that extrapolating its success to the entire healthcare ecosystem is flawed.
• He cites evidence from the 340B program as an example where government-driven price reductions may cause commercial market prices to rise via "hydraulic effects."
• The core argument against negotiation is that it threatens the return on investment necessary to sustain the biomedical innovation ecosystem.

Lobbying, Legislative History, and Future Outlook

• Cassidy attributes industry lobbying resistance to the fact that beneficiaries of the status quo (insurers, providers, private equity) actively oppose change, while patients who would benefit often remain unaware and unorganized.
• He references the Cassidy-Hassan "STOP Act" on surprise medical billing, which the CBO estimates will save $17 billion and received initial endorsement from AHIP before shifting to the House version.
• Rejecting the premise that Congress has been inactive, Cassidy lists past successes including the Vaccines for Children program, the Hatch-Waxman Act, and the creation of Medicare Part D.
• When asked for the single most critical question for the upcoming panel, Cassidy asks: "How do we make healthcare more affordable while respecting the fact that you have to encourage innovation?"
• Cassidy warns against setting payment rates below the cost of doing business, which could drive providers out of practice or force rural hospitals to close.
• Looking forward to the end of the year, Cassidy estimates a 60% probability that a drug pricing package will be enacted by December 31st.